Net Income

Amid a volatile market, Rock Tech Lithium's latest funding from existing investors signals strong confidence in its strategy to build a local battery supply chain.

As Wix prepares for a key investor chat, all eyes are on its AI strategy, recent market turbulence, and its path to sustained profitable growth.

A medical device firm is delegating its $163M Solana treasury, partnering with The Tie to forge a new path for institutional crypto adoption.

Hanks for Our Troops coffee hits Walmart shelves, channeling 100% of profits to veteran charities. But can celebrity star power brew sustainable change?

At Expo West, GELITA unveils advanced collagen solutions, including OPTIBAR®, tackling major challenges in the booming high-protein, low-sugar snack market.

Amid surging demand, Highspring adds key execs and expands to Dublin and Lisbon, signaling a major play in the global professional services market.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

With promising preclinical data and Australian trial approval, Kivu’s KIVU-305 aims to overcome past failures in targeting aggressive solid tumors.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

The spirits giant faces a steep sales decline and a massive write-down, pivoting to premium brands and operational fixes amid an industry-wide hangover.

AI-first firms face a hidden 'tax,' taking 80 days longer and paying 135% more to recover from cyberattacks, a new report from Fastly reveals.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

In its first report as a public company, Medline posts $28.4B in annual sales but faces declining net income from tariffs and IPO costs.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.